{"gene":"CFHR1","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2009,"finding":"CFHR1 (FHR-1) inhibits complement C5 convertase activity and blocks C5b surface deposition and MAC (terminal complex) formation on cell surfaces, acting distinctly from CFH which regulates at the C3 convertase level; both proteins bind to the same or similar sites on cellular surfaces, with CFHR1 gain of activity presumed to be at the expense of CFH-mediated C3 convertase inhibition.","method":"In vitro complement assays (C5 convertase inhibition, C5b deposition assay, MAC formation assay), binding competition studies on cell surfaces","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — multiple in vitro functional assays with defined mechanistic readouts, replicated across independent cohorts","pmids":["19528535"],"is_preprint":false},{"year":2013,"finding":"Native FHR1, FHR2, and FHR5 circulate in plasma as homo- and hetero-oligomeric complexes mediated by conserved N-terminal SCR domains. A C3G-associated CFHR1 mutation duplicating the N-terminal domain caused unusually large multimeric FHR complexes with increased avidity for C3b, iC3b, and C3dg, and enhanced competition with CFH in surface plasmon resonance studies and hemolytic assays.","method":"SPR (surface plasmon resonance), hemolytic assays, biochemical characterization of mutant FHR1 oligomers, plasma protein analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution and SPR with mutagenesis, multiple orthogonal methods in single rigorous study","pmids":["23728178"],"is_preprint":false},{"year":2016,"finding":"CFHR1 dimerization is necessary for effective binding to C3b and C3d, and for competition with CFH. The C3b/C3d:CFHR1 binding interface is identical to that of CFH SCR19-20 with C3b. CFHR1 also competes with the CFH splice variant CFHL-1 for C3b binding, sterically blocking both C-terminal and N-terminal CFH interactions with C3b.","method":"Site-directed mutagenesis, ELISA-based binding assays, functional hemolytic assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis combined with functional and binding assays, multiple orthogonal approaches","pmids":["27814381"],"is_preprint":false},{"year":2017,"finding":"FHR-1 binds to monomeric CRP (but not native pentameric CRP) via its C-terminal domains. FHR-1/CRP interactions increase complement activation via the classical and alternative pathways on extracellular matrix and necrotic cell surfaces. FHR-1 also binds C3b and allows C3 convertase formation, thereby enhancing rather than inhibiting complement activation. FHR-1 did not inhibit terminal complement complex formation induced by zymosan.","method":"Binding assays (ELISA), complement activation assays on surfaces (ECM, necrotic cells), C3 convertase formation assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal in vitro assays establishing binding and functional consequences","pmids":["28533443"],"is_preprint":false},{"year":2017,"finding":"FHR-1 and FHR-2 form homodimers and FHR-1/FHR-2 heterodimers in human plasma; FHR-5 circulates only as homodimer. FRET analysis demonstrated rapid monomer exchange between FHR dimers. In CFHR1-deletion individuals, FHR-1/1 and FHR-1/2 dimers were absent. FHR-5/5 homodimers showed strong heparin binding affinity.","method":"ELISA, FRET, ex vivo serum analysis from deletion individuals, recombinant protein analysis","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1–2 — FRET and ex vivo validation in deletion individuals, multiple orthogonal methods","pmids":["29093712"],"is_preprint":false},{"year":2019,"finding":"FHR1 selectively binds to necrotic cells via its N-terminus and triggers NLRP3 inflammasome activation in blood-derived human monocytes, leading to secretion of IL-1β, TNFα, IL-18, and IL-6. This signaling is mediated via the G-protein coupled receptor EMR2 through the phospholipase C pathway, independent of complement. FHR1, but not FH, FHR2, or FHR3, drove this inflammatory response.","method":"In vitro binding assays, inflammasome activation assay (NLRP3), cytokine secretion (ELISA), receptor identification (EMR2), pharmacological pathway inhibition (PLC pathway), staining of patient tissues","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal in vitro methods identifying receptor, pathway, and functional outcome; validated in patient tissue","pmids":["31273197"],"is_preprint":false},{"year":2021,"finding":"FHR-1 lacks the capacity to bind sialic acids (unlike CFH), which prevents C3b-binding competition between FH and FHR-1 on host-cell surfaces under normal conditions. aHUS-associated FHR-1 mutants are pathogenic because they have acquired sialic acid-binding capacity, increasing FHR-1 avidity for surface-bound C3-activated fragments and enabling competition with FH. FHR-1 also binds native C3 in addition to C3b, iC3b, and C3dg, and surface-bound FHR-1 promotes complement activation by attracting native C3 to the cell surface.","method":"Biochemical assays, immunological assays, NMR spectroscopy, computational modeling of FHR-1 mutants, functional complement activation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — NMR, biochemistry, and functional assays combined with mutagenesis in a single rigorous study","pmids":["33651882"],"is_preprint":false},{"year":2010,"finding":"CFHR1 binds to streptococcal Scl1.6 and Scl1.55 proteins via its conserved C-terminal SCR3-5 attachment region; binding is affected by ionic strength and heparin. CFHR1 binding to streptococcal surfaces is at the expense of CFH-mediated C3 convertase regulatory function but provides terminal complement control (C5 convertase/MAC level). CFH mutations associated with aHUS blocked CFHR1 interaction with Scl1 proteins.","method":"Pulldown/binding assays, complement functional assays (C3 convertase regulation), mutagenesis of binding domains, ionic strength/heparin competition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — domain-level binding characterization with functional complement assays, multiple conditions tested","pmids":["20855886"],"is_preprint":false},{"year":2020,"finding":"FHR-1 and FHR-5 bind to plasmid DNA and human genomic DNA, inhibiting FH binding to DNA and reducing FH cofactor activity. Both FHRs also bind to late apoptotic and necrotic cells, recruit monomeric CRP and pentraxin 3, and FHR-pentraxin interactions promote enhanced activation of both classical and alternative complement pathways on dead cells when exposed to human serum.","method":"Binding assays (ELISA, pulldown), complement activation assays on DNA and dead cells, cofactor activity assay","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple in vitro functional assays with defined mechanistic readouts","pmids":["32765490"],"is_preprint":false},{"year":2022,"finding":"FHR1 binds extracellular matrix components laminin, fibromodulin, osteoadherin, and PRELP through its C-terminal CCP domains 4-5. FHR1 inhibits FH binding to these ECM ligands in a dose-dependent manner, reducing FH cofactor activity, and enhances alternative complement pathway activation on immobilized ECM proteins, resulting in increased C3-fragment, factor B, and C5b-9 deposition.","method":"Binding assays (ELISA/SPR), cofactor activity assay, complement activation assay on immobilized ECM proteins, domain mapping","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1–2 — domain-level binding mapped with functional complement consequence, multiple ECM ligands and orthogonal assays","pmids":["35392081"],"is_preprint":false},{"year":2014,"finding":"A novel CFHR1/CFH hybrid fusion protein containing the first four SCRs of FHR1 and the terminal SCR20 of CFH acts as a competitive antagonist of FH. In an FH-dependent hemolysis assay, the hybrid protein caused sheep erythrocyte lysis, and sera from carriers induced more C5b-9 deposition on endothelial cells than control serum.","method":"FH-dependent hemolysis assay, C5b-9 deposition assay on endothelial cells, purification of hybrid protein from patient serum","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 1–2 — functional assays with patient-derived and recombinant proteins, multiple readouts","pmids":["24904082"],"is_preprint":false},{"year":2022,"finding":"The aHUS-associated FHR1*B isoform (CFHR1*B haplotype) exhibits higher C3b-binding capacity and stronger binding to necrotic cells than FHR1*A. FHR1*B shows stronger interference with FH-mediated cofactor function (less C3b cleavage) and stronger deregulation of FH inhibition of C3bBb assembly. FHR1*B also triggers higher IL-1β and IL-6 secretion from monocytes than FHR1*A.","method":"Homology modeling, recombinant protein expression, C3b binding assays, cofactor assay, C3 convertase assay, cytokine secretion assay","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays, single lab study","pmids":["35126388"],"is_preprint":false},{"year":2018,"finding":"FHR-1 competes with FH for binding to Plasmodium falciparum surfaces (intraerythrocytic schizonts and merozoites). FHR-1 accumulates on parasite surfaces and impairs C3b inactivation and parasite viability; FHR-1-deficient serum showed increased FH binding to parasites, and adding recombinant FHR-1 decreased FH binding.","method":"Binding competition assays with FHR-1-deficient serum and recombinant FHR-1, C3b inactivation assay, parasite viability assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal binding competition confirmed with deficient serum and recombinant protein, functional consequence measured","pmids":["30455399"],"is_preprint":false},{"year":2009,"finding":"Leptospiral immunoglobulin-like (Lig) proteins mediate acquisition of FHR-1 from human serum onto the Leptospira surface, contributing to bacterial complement evasion. Competition assays showed FH and C4BP have distinct binding sites on Lig proteins.","method":"Serum acquisition assays, pulldown, competition binding assays","journal":"The Journal of infectious diseases","confidence":"Medium","confidence_rationale":"Tier 2–3 — pulldown and competition assays demonstrating specific binding, single lab","pmids":["22291192"],"is_preprint":false},{"year":2020,"finding":"Deletion of mouse Cfhr1 (FHR-E, the murine homolog of human FHR-1) enhanced LPS-induced alternative complement pathway activation both in vitro and in vivo, and Cfhr1 knockout mice exhibited more severe sepsis and acute kidney injury in response to LPS challenge, demonstrating that FHR-E/FHR-1 regulates the alternative pathway in vivo.","method":"Cfhr1 knockout mouse model, LPS-induced sepsis/AKI model, complement activation assays in vitro and in vivo","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO mouse with defined phenotypic readout in vivo and in vitro","pmids":["32636836"],"is_preprint":false},{"year":2025,"finding":"FHR1 accumulates below the retinal pigment epithelium (RPE) in AMD. FHR1 signals through the receptor EMR2 (EGF-like module-containing mucin-like hormone receptor 1) on RPE and mononuclear phagocytes (MPs) to induce Ca2+ signaling and gene expression changes. muFHR1 deletion in mice significantly reduced mononuclear phagocyte invasion and neoangiogenesis in laser-induced choroidal neovascularization (CNV) model, establishing an EMR2-dependent FHR1 signaling pathway promoting para-inflammation.","method":"AMD donor tissue immunostaining, murine AMD models (RNAseq), EMR2 receptor identification, Ca2+ signaling assay in RPE cells, muFHR1 KO mouse in laser-induced CNV model","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 — receptor identification with Ca2+ signaling assay and KO mouse model with defined phenotype, single study","pmids":["40611130"],"is_preprint":false},{"year":2016,"finding":"CFHR1-modified neural stem cells (NSCs) blocked complement activation cascade and inhibited membrane attack complex formation in a neuromyelitis optica spectrum disorder model, protecting endogenous and transplanted NSC-differentiated astrocytes from immune-mediated damage.","method":"Engineered NSC transplantation in NMOSD model, complement activation assay, MAC formation assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 — functional in vivo model with complement-specific readouts, single lab","pmids":["27671112"],"is_preprint":false},{"year":2024,"finding":"Deletion of muFHR1 (mouse homolog of FHR-1) in ApoE-/- mice normalized cholesterol levels, reduced inflammation and plaque formation. muFHR1 deletion enhanced lipid conversion in the liver (RNAseq), and muFHR1 was found to direct oxLDL uptake by macrophages, supporting foam cell formation and plaque development.","method":"muFHR1-/- ApoE-/- double knockout mouse model, RNAseq, cholesterol measurements, plaque quantification","journal":"International journal of medical sciences","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO mouse with defined atherosclerosis phenotype, RNAseq mechanistic support","pmids":["41583528"],"is_preprint":false},{"year":2019,"finding":"FHR-1 circulates on extracellular vesicles and is deposited in atherosclerotic plaques. Surface-bound FHR-1 induces expression of pro-inflammatory cytokines and tissue factor in monocytes and neutrophils.","method":"Isolation of FHR-1 from plasma/extracellular vesicles, immunostaining of plaques, cytokine/tissue factor induction assays in monocytes and neutrophils","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 — multiple cell-based functional assays with protein isolated from human plasma, single lab","pmids":["34795372"],"is_preprint":false},{"year":2009,"finding":"Patients lacking CFHR1 (but not those lacking CFHR3 alone) present with anti-FH autoantibodies, suggesting that CFHR1 deficiency specifically promotes generation of anti-CFH autoantibodies, possibly due to lack of CFHR1 as an immune tolerance antigen sharing epitopes with CFH.","method":"Proteomics strategy to analyze CFHR proteins in plasma, genotype-phenotype correlation in aHUS cohorts","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 — genotype-phenotype correlation with proteomics validation, replicated across patient cohorts","pmids":["19745068"],"is_preprint":false},{"year":2024,"finding":"Cfhr1 gene knockout in mice led to excessive alternative complement pathway activation and enhanced C3a formation in lung tissues following S. aureus infection, resulting in higher bacterial loads in lungs and exacerbated sepsis-induced acute lung injury.","method":"Cfhr1-knockout mouse model, S. aureus i.v. infection model, C3a measurement, bacterial CFU counts, cytokine/complement factor measurements, RNA-seq","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO mouse with defined infectious phenotype and complement readout, single lab","pmids":["39128222"],"is_preprint":false}],"current_model":"CFHR1 (FHR-1) is a circulating plasma complement protein that forms homo- and heterodimers/oligomers via conserved N-terminal domains, and acts primarily as a context-dependent modulator of complement activation: on cell surfaces and extracellular matrices it competes with CFH for C3b/C3dg binding (via its C-terminal SCR3-5 domains) to derepress complement, inhibits C5 convertase and MAC formation, binds necrotic cells via its N-terminus to trigger NLRP3 inflammasome activation through the EMR2 G-protein coupled receptor (independent of complement), and can bind ECM components, DNA, pentraxins (CRP, PTX3), and microbial surfaces—collectively indicating that FHR-1 fine-tunes the balance between complement activation and suppression while also driving sterile inflammation at sites of necrosis."},"narrative":{"teleology":[{"year":2009,"claim":"Establishing that FHR-1 acts at the terminal complement pathway: FHR-1 was shown to inhibit C5 convertase and MAC formation independently of CFH's C3 convertase regulation, revealing a distinct level of complement control and raising the question of how FHR-1 and CFH partition regulatory functions on surfaces.","evidence":"In vitro C5 convertase inhibition, C5b deposition, and MAC formation assays with binding competition on cell surfaces","pmids":["19528535"],"confidence":"High","gaps":["Whether FHR-1 C5 convertase inhibition operates in vivo","Whether terminal pathway regulation is the dominant activity or context-dependent","The structural basis for C5 convertase recognition by FHR-1"]},{"year":2009,"claim":"Linking CFHR1 deficiency to autoimmune pathology: CFHR1-deficient aHUS patients specifically generated anti-FH autoantibodies, suggesting FHR-1 may serve as an immune tolerance antigen for CFH due to shared epitopes.","evidence":"Proteomics of CFHR proteins in plasma combined with genotype-phenotype correlation in aHUS cohorts","pmids":["19745068"],"confidence":"Medium","gaps":["Mechanism of tolerance breakdown in CFHR1 deficiency not demonstrated experimentally","Correlation does not establish causality — could reflect linked deletions","No B-cell or T-cell epitope mapping performed"]},{"year":2010,"claim":"Demonstrating microbial surface exploitation: FHR-1 was recruited to group A streptococcal surfaces via Scl1 proteins through its C-terminal SCR3–5, displacing CFH and thereby shifting complement regulation from C3 convertase to terminal pathway level.","evidence":"Pulldown and competition binding assays with domain mutagenesis and complement functional assays on streptococcal surfaces","pmids":["20855886"],"confidence":"High","gaps":["In vivo relevance of FHR-1 recruitment in streptococcal infection not established","Whether this mechanism extends to other Gram-positive pathogens"]},{"year":2013,"claim":"Revealing that dimerization/oligomerization is functionally critical: native FHR-1 circulates as dimers that enhance avidity for C3b/iC3b/C3dg; a C3G-associated CFHR1 N-terminal duplication created abnormally large multimers with pathologically enhanced CFH competition, establishing that oligomeric state directly controls complement deregulatory potency.","evidence":"SPR, hemolytic assays, and biochemical analysis of patient-derived mutant FHR1 oligomers","pmids":["23728178"],"confidence":"High","gaps":["High-resolution structure of the dimerization interface not determined","How oligomeric state is regulated in vivo"]},{"year":2014,"claim":"Establishing fusion proteins as competitive antagonists of CFH: a naturally occurring CFHR1/CFH hybrid protein containing FHR-1 N-terminal dimerization domains fused to CFH SCR20 competed with FH and caused complement-mediated hemolysis and C5b-9 deposition on endothelial cells.","evidence":"FH-dependent hemolysis assay and C5b-9 deposition on endothelial cells with patient-derived hybrid protein","pmids":["24904082"],"confidence":"High","gaps":["Prevalence and penetrance of hybrid gene in broader populations","Whether hybrid formation requires specific genomic rearrangement hotspots"]},{"year":2016,"claim":"Defining the structural basis for CFH competition: mutagenesis showed that FHR-1 dimerization is necessary for C3b/C3d binding, that the binding interface is identical to CFH SCR19-20, and that FHR-1 sterically blocks both C-terminal and N-terminal CFH interactions with C3b, unifying the competitive deregulation model.","evidence":"Site-directed mutagenesis, ELISA binding assays, and hemolytic functional assays","pmids":["27814381"],"confidence":"High","gaps":["Crystal or cryo-EM structure of FHR-1 dimer bound to C3b not available","Relative affinities under physiological conditions on cell surfaces"]},{"year":2017,"claim":"Resolving how FHR-1 promotes complement activation on damaged tissues: FHR-1 binds monomeric CRP and permits C3 convertase formation on ECM and necrotic cells, enhancing both classical and alternative pathway activation — contradicting the earlier view that FHR-1 primarily inhibits terminal complement.","evidence":"ELISA binding assays, complement activation assays on ECM and necrotic cell surfaces, C3 convertase formation assay","pmids":["28533443"],"confidence":"High","gaps":["Which activity predominates in vivo — complement inhibition or activation — remains context-dependent","Whether CRP conformational state is controlled at injury sites"]},{"year":2017,"claim":"Characterizing the dynamics of FHR dimeric pools: FRET demonstrated rapid monomer exchange between FHR-1 homodimers and FHR-1/FHR-2 heterodimers in plasma, and CFHR1-deletion individuals confirmed loss of all FHR-1-containing dimers.","evidence":"FRET, ELISA, and ex vivo serum analysis from CFHR1-deletion individuals","pmids":["29093712"],"confidence":"High","gaps":["Functional differences between FHR-1/1 homodimers and FHR-1/2 heterodimers not defined","Whether monomer exchange is regulated or stochastic"]},{"year":2019,"claim":"Discovering a complement-independent inflammatory function: FHR-1 binds necrotic cells via its N-terminus and signals through the GPCR EMR2 to activate the NLRP3 inflammasome via the PLC pathway, inducing IL-1β, TNFα, IL-18, and IL-6 secretion from monocytes — a function unique to FHR-1 among FHR family members.","evidence":"In vitro binding, inflammasome activation, cytokine ELISA, EMR2 receptor identification, PLC pathway pharmacological inhibition, patient tissue staining","pmids":["31273197"],"confidence":"High","gaps":["The FHR-1/EMR2 binding interface not structurally defined","Whether other cell types respond to FHR-1 via EMR2","In vivo contribution of FHR-1–EMR2 axis to sterile inflammation not demonstrated at that time"]},{"year":2019,"claim":"Extending FHR-1 to atherosclerosis: FHR-1 was found on circulating extracellular vesicles and deposited in atherosclerotic plaques, where surface-bound FHR-1 induced proinflammatory cytokine and tissue factor expression in monocytes and neutrophils.","evidence":"Isolation from plasma EVs, immunostaining of human plaques, cytokine/tissue factor induction assays","pmids":["34795372"],"confidence":"Medium","gaps":["Causal role of FHR-1 in plaque formation not established by this study alone","Whether EV-associated FHR-1 has different activity than soluble FHR-1"]},{"year":2020,"claim":"Demonstrating in vivo complement regulatory role: Cfhr1 knockout mice showed enhanced alternative pathway activation and more severe sepsis/acute kidney injury upon LPS challenge, establishing that FHR-1 has a net protective, complement-dampening function in vivo during endotoxemia.","evidence":"Cfhr1 knockout mouse model with LPS-induced sepsis/AKI, complement activation assays in vitro and in vivo","pmids":["32636836"],"confidence":"Medium","gaps":["Mouse FHR-E is not identical to human FHR-1 — species-specific differences in complement regulation","Whether the in vivo effect is direct C5 convertase inhibition or indirect via CFH modulation"]},{"year":2020,"claim":"Broadening ligand repertoire to DNA and pentraxins: FHR-1 binds DNA, recruits monomeric CRP and PTX3 to dead cells, and inhibits FH binding to DNA, collectively enhancing complement activation via both classical and alternative pathways on apoptotic/necrotic surfaces.","evidence":"ELISA/pulldown binding assays, complement activation assays on DNA and dead cells, cofactor activity assays","pmids":["32765490"],"confidence":"High","gaps":["Whether DNA-bound FHR-1 contributes to lupus-like autoimmunity","Relative contributions of CRP vs PTX3 recruitment in vivo"]},{"year":2021,"claim":"Resolving why FHR-1 does not normally compete with CFH on host cells: wild-type FHR-1 lacks sialic acid binding capacity, preventing effective competition on sialylated host surfaces; aHUS-associated mutations confer sialic acid binding, enabling pathological CFH displacement and surface complement activation.","evidence":"NMR spectroscopy, biochemical binding assays, computational modeling of FHR-1 mutants, functional complement activation assays","pmids":["33651882"],"confidence":"High","gaps":["Whether sialic acid binding distinguishes pathogenic from benign FHR-1 variants genome-wide","Structural mechanism of sialic acid recognition by mutant FHR-1"]},{"year":2022,"claim":"Defining ECM as a major surface for FHR-1 activity: FHR-1 binds laminin, fibromodulin, osteoadherin, and PRELP via CCP4-5, displaces FH, and enhances alternative pathway activation with increased C3-fragment, factor B, and C5b-9 deposition on ECM surfaces.","evidence":"ELISA/SPR binding, domain mapping, cofactor activity, and complement activation on immobilized ECM proteins","pmids":["35392081"],"confidence":"High","gaps":["Whether ECM-bound FHR-1 contributes to fibrosis or tissue remodeling","In vivo validation of FHR-1 ECM interactions"]},{"year":2022,"claim":"Establishing that natural FHR-1 isoform variation modulates disease risk: the aHUS-associated FHR1*B isoform shows higher C3b binding, stronger CFH displacement, and greater inflammasome-activating capacity compared to FHR1*A, connecting common polymorphism to quantitative differences in both complement and inflammatory outputs.","evidence":"Recombinant FHR1*A vs *B proteins tested in C3b binding, cofactor, C3 convertase, and cytokine secretion assays","pmids":["35126388"],"confidence":"Medium","gaps":["Single lab study — independent replication needed","Population-level contribution of FHR1*B to aHUS risk not quantified"]},{"year":2024,"claim":"Connecting FHR-1 to metabolic inflammation: muFHR1 knockout in ApoE-/- mice normalized cholesterol, reduced plaque formation, and decreased foam cell development, with muFHR1 shown to direct oxLDL uptake by macrophages.","evidence":"muFHR1-/- ApoE-/- double knockout mouse model with RNAseq, cholesterol measurements, and plaque quantification","pmids":["41583528"],"confidence":"Medium","gaps":["Mechanism of FHR-1-mediated oxLDL uptake not defined at receptor level","Mouse-to-human translatability of metabolic phenotype uncertain"]},{"year":2025,"claim":"Validating the FHR-1/EMR2 axis in vivo in retinal disease: FHR-1 accumulates sub-RPE in AMD, signals through EMR2 on RPE and phagocytes to induce Ca2+ flux and transcriptional changes, and muFHR1 deletion significantly reduced phagocyte invasion and neoangiogenesis in laser-induced CNV, establishing a para-inflammatory signaling role in AMD.","evidence":"AMD donor tissue immunostaining, EMR2 receptor identification, Ca2+ signaling in RPE cells, muFHR1 KO mouse in laser-induced CNV model","pmids":["40611130"],"confidence":"Medium","gaps":["Whether therapeutic FHR-1 blockade or EMR2 antagonism protects against AMD progression","Contribution of complement-dependent vs complement-independent FHR-1 effects in the retina"]},{"year":null,"claim":"Open question: the context-dependent switch between FHR-1's complement-activating and complement-inhibiting functions, the structural basis of FHR-1/EMR2 signaling, and whether FHR-1 can be therapeutically targeted in complement-mediated and inflammatory diseases remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of FHR-1 dimer or FHR-1/EMR2 complex available","Quantitative partitioning of complement-inhibitory vs complement-activating functions across tissues and disease states not defined","No clinical trials targeting FHR-1 or the FHR-1/EMR2 axis reported"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,3,6,9]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[5,15]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,4,8,18]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[9]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,3,6,7,8,9,14,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,15]}],"complexes":["FHR-1 homodimer","FHR-1/FHR-2 heterodimer"],"partners":["CFH","FHR2","C3B","EMR2","CRP","PTX3"],"other_free_text":[]},"mechanistic_narrative":"CFHR1 (FHR-1) is a secreted complement regulatory protein that fine-tunes the balance between complement activation and suppression on cell surfaces, extracellular matrices, and microbial surfaces, while also driving complement-independent sterile inflammation. FHR-1 circulates as homo- and heterodimers (with FHR-2) whose N-terminal dimerization domains are required for effective C3b/C3d binding; its C-terminal SCR3–5 domains share the same C3b-binding interface as CFH SCR19-20, enabling dose-dependent competition with CFH that displaces CFH cofactor activity and promotes alternative pathway amplification on surfaces including ECM components (laminin, fibromodulin), DNA, necrotic cells, pentraxins (monomeric CRP, PTX3), and microbial targets [PMID:27814381, PMID:23728178, PMID:35392081, PMID:32765490, PMID:28533443]. While FHR-1 can inhibit C5 convertase and terminal complement complex formation under certain conditions [PMID:19528535], murine knockout studies demonstrate that loss of FHR-1 leads to excessive alternative pathway activation and worsened sepsis-associated organ injury, confirming a net regulatory role in vivo [PMID:32636836, PMID:39128222]. Independently of complement, FHR-1 binds necrotic cells via its N-terminus and signals through the GPCR EMR2 to activate the NLRP3 inflammasome via the phospholipase C pathway, driving IL-1β, TNFα, and IL-6 secretion from monocytes, and promoting mononuclear phagocyte invasion and neoangiogenesis in retinal disease models [PMID:31273197, PMID:40611130]."},"prefetch_data":{"uniprot":{"accession":"Q03591","full_name":"Complement factor H-related protein 1","aliases":["H factor-like protein 1","FHL-1","H-factor-like 1","H36"],"length_aa":330,"mass_kda":37.7,"function":"Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH. Can associate with lipoproteins and may play a role in lipid metabolism","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q03591/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CFHR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1165,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CFHR1","total_profiled":1310},"omim":[{"mim_id":"610698","title":"MACULAR DEGENERATION, AGE-RELATED, 4; ARMD4","url":"https://www.omim.org/entry/610698"},{"mim_id":"605337","title":"COMPLEMENT FACTOR H-RELATED 4; CFHR4","url":"https://www.omim.org/entry/605337"},{"mim_id":"605336","title":"COMPLEMENT FACTOR H-RELATED 3; CFHR3","url":"https://www.omim.org/entry/605336"},{"mim_id":"603075","title":"MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1","url":"https://www.omim.org/entry/603075"},{"mim_id":"600889","title":"COMPLEMENT FACTOR H-RELATED 2; CFHR2","url":"https://www.omim.org/entry/600889"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":1937.3}],"url":"https://www.proteinatlas.org/search/CFHR1"},"hgnc":{"alias_symbol":["H36-1","FHR1","CFHL","H36-2"],"prev_symbol":["HFL1","CFHL1","CFHR1P","HFL2","CFHL1P"]},"alphafold":{"accession":"Q03591","domains":[{"cath_id":"2.10.70.10","chopping":"23-83","consensus_level":"high","plddt":88.7607,"start":23,"end":83},{"cath_id":"2.10.70.10","chopping":"86-143","consensus_level":"high","plddt":92.3117,"start":86,"end":143},{"cath_id":"2.10.70.10","chopping":"157-204","consensus_level":"high","plddt":92.85,"start":157,"end":204},{"cath_id":"2.10.70.10","chopping":"218-263","consensus_level":"high","plddt":95.0235,"start":218,"end":263},{"cath_id":"2.10.70.10","chopping":"267-330","consensus_level":"high","plddt":86.7956,"start":267,"end":330}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03591","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q03591-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q03591-F1-predicted_aligned_error_v6.png","plddt_mean":89.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CFHR1","jax_strain_url":"https://www.jax.org/strain/search?query=CFHR1"},"sequence":{"accession":"Q03591","fasta_url":"https://rest.uniprot.org/uniprotkb/Q03591.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q03591/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03591"}},"corpus_meta":[{"pmid":"16998489","id":"PMC_16998489","title":"A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration.","date":"2006","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16998489","citation_count":386,"is_preprint":false},{"pmid":"17367211","id":"PMC_17367211","title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.","date":"2007","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17367211","citation_count":291,"is_preprint":false},{"pmid":"19528535","id":"PMC_19528535","title":"Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19528535","citation_count":221,"is_preprint":false},{"pmid":"19745068","id":"PMC_19745068","title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19745068","citation_count":175,"is_preprint":false},{"pmid":"23728178","id":"PMC_23728178","title":"C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23728178","citation_count":162,"is_preprint":false},{"pmid":"25205734","id":"PMC_25205734","title":"Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy.","date":"2014","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/25205734","citation_count":132,"is_preprint":false},{"pmid":"19435718","id":"PMC_19435718","title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.","date":"2009","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19435718","citation_count":127,"is_preprint":false},{"pmid":"22291192","id":"PMC_22291192","title":"Leptospiral immunoglobulin-like proteins interact with human complement regulators factor H, FHL-1, FHR-1, and C4BP.","date":"2012","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22291192","citation_count":119,"is_preprint":false},{"pmid":"23613724","id":"PMC_23613724","title":"Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23613724","citation_count":106,"is_preprint":false},{"pmid":"24904082","id":"PMC_24904082","title":"A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.","date":"2014","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/24904082","citation_count":82,"is_preprint":false},{"pmid":"23873044","id":"PMC_23873044","title":"Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23873044","citation_count":76,"is_preprint":false},{"pmid":"18084039","id":"PMC_18084039","title":"Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18084039","citation_count":73,"is_preprint":false},{"pmid":"26940089","id":"PMC_26940089","title":"Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese.","date":"2016","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26940089","citation_count":72,"is_preprint":false},{"pmid":"22494769","id":"PMC_22494769","title":"Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein.","date":"2012","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/22494769","citation_count":60,"is_preprint":false},{"pmid":"31273197","id":"PMC_31273197","title":"Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31273197","citation_count":59,"is_preprint":false},{"pmid":"10781834","id":"PMC_10781834","title":"Complement factor H: sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10781834","citation_count":49,"is_preprint":false},{"pmid":"26163426","id":"PMC_26163426","title":"Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.","date":"2015","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26163426","citation_count":49,"is_preprint":false},{"pmid":"28533443","id":"PMC_28533443","title":"FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28533443","citation_count":47,"is_preprint":false},{"pmid":"23880784","id":"PMC_23880784","title":"A novel hybrid CFHR1/CFH gene causes atypical hemolytic uremic syndrome.","date":"2013","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/23880784","citation_count":43,"is_preprint":false},{"pmid":"20855886","id":"PMC_20855886","title":"Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20855886","citation_count":41,"is_preprint":false},{"pmid":"29114042","id":"PMC_29114042","title":"Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.","date":"2017","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/29114042","citation_count":39,"is_preprint":false},{"pmid":"4352176","id":"PMC_4352176","title":"Genetic and biochemical investigation of the Escherichia coli mutant hfl-1 which is lysogenized at high frequency by bacteriophage lambda.","date":"1973","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/4352176","citation_count":39,"is_preprint":false},{"pmid":"29093712","id":"PMC_29093712","title":"Factor H-Related (FHR)-1 and FHR-2 Form Homo- and Heterodimers, while FHR-5 Circulates Only As Homodimer in Human Plasma.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29093712","citation_count":38,"is_preprint":false},{"pmid":"22247456","id":"PMC_22247456","title":"Relevance of complement factor H-related 1 (CFHR1) genotypes in age-related macular degeneration.","date":"2012","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/22247456","citation_count":37,"is_preprint":false},{"pmid":"24557084","id":"PMC_24557084","title":"Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration.","date":"2014","source":"JAMA ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/24557084","citation_count":36,"is_preprint":false},{"pmid":"28729035","id":"PMC_28729035","title":"A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.","date":"2017","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/28729035","citation_count":36,"is_preprint":false},{"pmid":"25237378","id":"PMC_25237378","title":"Vitamin D Inhibits Expression and Activity of Matrix Metalloproteinase in Human Lung Fibroblasts (HFL-1) Cells.","date":"2014","source":"Tuberculosis and respiratory diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25237378","citation_count":33,"is_preprint":false},{"pmid":"26911452","id":"PMC_26911452","title":"Specific regulation of PRMT1 expression by PIAS1 and RKIP in BEAS-2B epithelia cells and HFL-1 fibroblasts in lung inflammation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26911452","citation_count":33,"is_preprint":false},{"pmid":"19951285","id":"PMC_19951285","title":"Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.","date":"2009","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/19951285","citation_count":32,"is_preprint":false},{"pmid":"23982707","id":"PMC_23982707","title":"Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene.","date":"2013","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/23982707","citation_count":31,"is_preprint":false},{"pmid":"24450762","id":"PMC_24450762","title":"The Rbf1, Hfl1 and Dbp4 of Candida albicans regulate common as well as transcription factor-specific mitochondrial and other cell activities.","date":"2014","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24450762","citation_count":29,"is_preprint":false},{"pmid":"32765490","id":"PMC_32765490","title":"Interaction of the Factor H Family Proteins FHR-1 and FHR-5 With DNA and Dead Cells: Implications for the Regulation of Complement Activation and Opsonization.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32765490","citation_count":29,"is_preprint":false},{"pmid":"35401574","id":"PMC_35401574","title":"An Autoantigen Atlas From Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35401574","citation_count":25,"is_preprint":false},{"pmid":"33651882","id":"PMC_33651882","title":"Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33651882","citation_count":24,"is_preprint":false},{"pmid":"27671112","id":"PMC_27671112","title":"CFHR1-Modified Neural Stem Cells Ameliorated Brain Injury in a Mouse Model of Neuromyelitis Optica Spectrum Disorders.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27671112","citation_count":24,"is_preprint":false},{"pmid":"27814381","id":"PMC_27814381","title":"Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27814381","citation_count":22,"is_preprint":false},{"pmid":"35392081","id":"PMC_35392081","title":"Complement Factor H-Related Proteins FHR1 and FHR5 Interact With Extracellular Matrix Ligands, Reduce Factor H Regulatory Activity and Enhance Complement Activation.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35392081","citation_count":22,"is_preprint":false},{"pmid":"30455399","id":"PMC_30455399","title":"Cutting Edge: FHR-1 Binding Impairs Factor H-Mediated Complement Evasion by the Malaria Parasite Plasmodium falciparum.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30455399","citation_count":21,"is_preprint":false},{"pmid":"34795372","id":"PMC_34795372","title":"Factor H-related protein 1 (FHR-1) is associated with atherosclerotic cardiovascular disease.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34795372","citation_count":19,"is_preprint":false},{"pmid":"28104134","id":"PMC_28104134","title":"Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.","date":"2017","source":"Transplantation proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/28104134","citation_count":19,"is_preprint":false},{"pmid":"34088313","id":"PMC_34088313","title":"Membrane recruitment of Atg8 by Hfl1 facilitates turnover of vacuolar membrane proteins in yeast cells approaching stationary phase.","date":"2021","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/34088313","citation_count":17,"is_preprint":false},{"pmid":"32636836","id":"PMC_32636836","title":"Deficiency of Mouse FHR-1 Homolog, FHR-E, Accelerates Sepsis, and Acute Kidney Injury Through Enhancing the LPS-Induced Alternative Complement Pathway.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32636836","citation_count":17,"is_preprint":false},{"pmid":"31485643","id":"PMC_31485643","title":"CFHR1 is a potentially downregulated gene in lung adenocarcinoma.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/31485643","citation_count":14,"is_preprint":false},{"pmid":"27528699","id":"PMC_27528699","title":"Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27528699","citation_count":14,"is_preprint":false},{"pmid":"33501444","id":"PMC_33501444","title":"An Autoantigen Atlas from Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19.","date":"2021","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33501444","citation_count":14,"is_preprint":false},{"pmid":"22848687","id":"PMC_22848687","title":"Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22848687","citation_count":14,"is_preprint":false},{"pmid":"33777961","id":"PMC_33777961","title":"The Transcription Factor C/EBPβ Promotes HFL-1 Cell Migration, Proliferation, and Inflammation by Activating lncRNA HAS2-AS1 in Hypoxia.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33777961","citation_count":14,"is_preprint":false},{"pmid":"34724668","id":"PMC_34724668","title":"Atypical Hemolytic Uremic Syndrome after ChAdOx1 nCoV-19 Vaccination in a Patient with Homozygous CFHR3/CFHR1 Gene Deletion.","date":"2021","source":"Nephron","url":"https://pubmed.ncbi.nlm.nih.gov/34724668","citation_count":13,"is_preprint":false},{"pmid":"28424685","id":"PMC_28424685","title":"Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28424685","citation_count":10,"is_preprint":false},{"pmid":"36068772","id":"PMC_36068772","title":"Diterpenoid alkaloids isolated from Delphinium trichophorum alleviate pulmonary fibrosis via the TGF-β/Smad pathway in 3T6 and HFL-1 cells.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36068772","citation_count":9,"is_preprint":false},{"pmid":"30945073","id":"PMC_30945073","title":"Altered Peripheral Blood Leucocyte Phenotype and Responses in Healthy Individuals with Homozygous Deletion of FHR1 and FHR3 Genes.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30945073","citation_count":8,"is_preprint":false},{"pmid":"37560477","id":"PMC_37560477","title":"Cryptotanshinone affects HFL-1 cells proliferation by inhibiting cytokines secretion in RAW264.7 cells and ameliorates inflammation and fibrosis in newborn rats with hyperoxia induced lung injury.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37560477","citation_count":8,"is_preprint":false},{"pmid":"28991129","id":"PMC_28991129","title":"A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.","date":"2018","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28991129","citation_count":8,"is_preprint":false},{"pmid":"29524412","id":"PMC_29524412","title":"Protective effect of methylallyl sulfone in the development of cigarette smoke extract-induced apoptosis in rats and HFL-1 cells.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29524412","citation_count":8,"is_preprint":false},{"pmid":"26087050","id":"PMC_26087050","title":"Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.","date":"2015","source":"Pediatric transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/26087050","citation_count":7,"is_preprint":false},{"pmid":"32258117","id":"PMC_32258117","title":"HYAL1 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits HFL-1 Fibroblast Proliferation When Upregulated.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32258117","citation_count":6,"is_preprint":false},{"pmid":"29225802","id":"PMC_29225802","title":"Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies.","date":"2017","source":"Clinical kidney journal","url":"https://pubmed.ncbi.nlm.nih.gov/29225802","citation_count":6,"is_preprint":false},{"pmid":"40611130","id":"PMC_40611130","title":"Factor-H-related protein 1 (FHR1), a promotor of para-inflammation in age-related macular degeneration.","date":"2025","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/40611130","citation_count":5,"is_preprint":false},{"pmid":"38030002","id":"PMC_38030002","title":"Complete biodegradation of fungicide carboxin and its metabolite aniline by Delftia sp. HFL-1.","date":"2023","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/38030002","citation_count":5,"is_preprint":false},{"pmid":"35617302","id":"PMC_35617302","title":"Copy number variation analysis using next-generation sequencing identifies the CFHR3/CFHR1 deletion in atypical hemolytic uremic syndrome: a case report.","date":"2022","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35617302","citation_count":4,"is_preprint":false},{"pmid":"35126388","id":"PMC_35126388","title":"Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35126388","citation_count":3,"is_preprint":false},{"pmid":"36851916","id":"PMC_36851916","title":"Structural modelling of human complement FHR1 and two of its synthetic derivatives provides insight into their in-vivo functions.","date":"2023","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/36851916","citation_count":3,"is_preprint":false},{"pmid":"34007337","id":"PMC_34007337","title":"Exogenous BMP9 promotes lung fibroblast HFL-1 cell activation via ALK1/Smad1/5 signaling in vitro.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34007337","citation_count":3,"is_preprint":false},{"pmid":"30715674","id":"PMC_30715674","title":"Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.","date":"2019","source":"CEN case reports","url":"https://pubmed.ncbi.nlm.nih.gov/30715674","citation_count":3,"is_preprint":false},{"pmid":"36755127","id":"PMC_36755127","title":"CFH-CFHR1 hybrid genes in two cases of atypical hemolytic uremic syndrome.","date":"2023","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36755127","citation_count":3,"is_preprint":false},{"pmid":"37147581","id":"PMC_37147581","title":"Atypical haemolytic uremic syndrome with refractory multiorgan involvement and heterozygous CFHR1/CFHR3 gene deletion.","date":"2023","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/37147581","citation_count":2,"is_preprint":false},{"pmid":"28604974","id":"PMC_28604974","title":"[Study on the CFHR1 level and its genetic polymorphisms in type 2 diabetes mellitus patients].","date":"2017","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28604974","citation_count":1,"is_preprint":false},{"pmid":"36070894","id":"PMC_36070894","title":"An Infant Case of Streptococcus Pneumoniae-Associated Thrombotic Microangiopathy with Heterozygous CFI Mutation and CFHR3-CFHR1 Deletion.","date":"2022","source":"The Tohoku journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36070894","citation_count":1,"is_preprint":false},{"pmid":"35852773","id":"PMC_35852773","title":"De novo systemic atypical hemolytic uremic syndrome in an ABO-incompatible living kidney transplant recipient with a novel pathogenic CFHR1 gene mutation successfully treated with eculizumab: a case report.","date":"2022","source":"Journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/35852773","citation_count":1,"is_preprint":false},{"pmid":"38286352","id":"PMC_38286352","title":"CFHR1 involvement in bile duct carcinoma: Insights from a data mining study.","date":"2024","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38286352","citation_count":1,"is_preprint":false},{"pmid":"38524137","id":"PMC_38524137","title":"Case report: A family of atypical hemolytic uremic syndrome involving a CFH::CFHR1 fusion gene and CFHR3-1-4-2 gene duplication.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38524137","citation_count":1,"is_preprint":false},{"pmid":"41583528","id":"PMC_41583528","title":"Deletion of the Mouse Homolog of Human FHR1 (muFHR1) Alleviates Atherosclerosis in ApoE-/- mice.","date":"2026","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41583528","citation_count":0,"is_preprint":false},{"pmid":"39128222","id":"PMC_39128222","title":"Cfhr1 gene deficiency exacerbates Staphylococcus aureus-induced sepsis and acute lung injury through complement alternative pathway hyperactivation.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39128222","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.13.24317290","title":"Rare predicted loss-of-function and damaging missense variants in<i>CFHR5</i>associate with protection from age-related macular degeneration","date":"2024-11-15","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.13.24317290","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39100,"output_tokens":5249,"usd":0.098017},"stage2":{"model":"claude-opus-4-6","input_tokens":8796,"output_tokens":4621,"usd":0.239258},"total_usd":0.337275,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"CFHR1 (FHR-1) inhibits complement C5 convertase activity and blocks C5b surface deposition and MAC (terminal complex) formation on cell surfaces, acting distinctly from CFH which regulates at the C3 convertase level; both proteins bind to the same or similar sites on cellular surfaces, with CFHR1 gain of activity presumed to be at the expense of CFH-mediated C3 convertase inhibition.\",\n      \"method\": \"In vitro complement assays (C5 convertase inhibition, C5b deposition assay, MAC formation assay), binding competition studies on cell surfaces\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple in vitro functional assays with defined mechanistic readouts, replicated across independent cohorts\",\n      \"pmids\": [\"19528535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Native FHR1, FHR2, and FHR5 circulate in plasma as homo- and hetero-oligomeric complexes mediated by conserved N-terminal SCR domains. A C3G-associated CFHR1 mutation duplicating the N-terminal domain caused unusually large multimeric FHR complexes with increased avidity for C3b, iC3b, and C3dg, and enhanced competition with CFH in surface plasmon resonance studies and hemolytic assays.\",\n      \"method\": \"SPR (surface plasmon resonance), hemolytic assays, biochemical characterization of mutant FHR1 oligomers, plasma protein analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution and SPR with mutagenesis, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"23728178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CFHR1 dimerization is necessary for effective binding to C3b and C3d, and for competition with CFH. The C3b/C3d:CFHR1 binding interface is identical to that of CFH SCR19-20 with C3b. CFHR1 also competes with the CFH splice variant CFHL-1 for C3b binding, sterically blocking both C-terminal and N-terminal CFH interactions with C3b.\",\n      \"method\": \"Site-directed mutagenesis, ELISA-based binding assays, functional hemolytic assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with functional and binding assays, multiple orthogonal approaches\",\n      \"pmids\": [\"27814381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FHR-1 binds to monomeric CRP (but not native pentameric CRP) via its C-terminal domains. FHR-1/CRP interactions increase complement activation via the classical and alternative pathways on extracellular matrix and necrotic cell surfaces. FHR-1 also binds C3b and allows C3 convertase formation, thereby enhancing rather than inhibiting complement activation. FHR-1 did not inhibit terminal complement complex formation induced by zymosan.\",\n      \"method\": \"Binding assays (ELISA), complement activation assays on surfaces (ECM, necrotic cells), C3 convertase formation assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal in vitro assays establishing binding and functional consequences\",\n      \"pmids\": [\"28533443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FHR-1 and FHR-2 form homodimers and FHR-1/FHR-2 heterodimers in human plasma; FHR-5 circulates only as homodimer. FRET analysis demonstrated rapid monomer exchange between FHR dimers. In CFHR1-deletion individuals, FHR-1/1 and FHR-1/2 dimers were absent. FHR-5/5 homodimers showed strong heparin binding affinity.\",\n      \"method\": \"ELISA, FRET, ex vivo serum analysis from deletion individuals, recombinant protein analysis\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — FRET and ex vivo validation in deletion individuals, multiple orthogonal methods\",\n      \"pmids\": [\"29093712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FHR1 selectively binds to necrotic cells via its N-terminus and triggers NLRP3 inflammasome activation in blood-derived human monocytes, leading to secretion of IL-1β, TNFα, IL-18, and IL-6. This signaling is mediated via the G-protein coupled receptor EMR2 through the phospholipase C pathway, independent of complement. FHR1, but not FH, FHR2, or FHR3, drove this inflammatory response.\",\n      \"method\": \"In vitro binding assays, inflammasome activation assay (NLRP3), cytokine secretion (ELISA), receptor identification (EMR2), pharmacological pathway inhibition (PLC pathway), staining of patient tissues\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal in vitro methods identifying receptor, pathway, and functional outcome; validated in patient tissue\",\n      \"pmids\": [\"31273197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FHR-1 lacks the capacity to bind sialic acids (unlike CFH), which prevents C3b-binding competition between FH and FHR-1 on host-cell surfaces under normal conditions. aHUS-associated FHR-1 mutants are pathogenic because they have acquired sialic acid-binding capacity, increasing FHR-1 avidity for surface-bound C3-activated fragments and enabling competition with FH. FHR-1 also binds native C3 in addition to C3b, iC3b, and C3dg, and surface-bound FHR-1 promotes complement activation by attracting native C3 to the cell surface.\",\n      \"method\": \"Biochemical assays, immunological assays, NMR spectroscopy, computational modeling of FHR-1 mutants, functional complement activation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR, biochemistry, and functional assays combined with mutagenesis in a single rigorous study\",\n      \"pmids\": [\"33651882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CFHR1 binds to streptococcal Scl1.6 and Scl1.55 proteins via its conserved C-terminal SCR3-5 attachment region; binding is affected by ionic strength and heparin. CFHR1 binding to streptococcal surfaces is at the expense of CFH-mediated C3 convertase regulatory function but provides terminal complement control (C5 convertase/MAC level). CFH mutations associated with aHUS blocked CFHR1 interaction with Scl1 proteins.\",\n      \"method\": \"Pulldown/binding assays, complement functional assays (C3 convertase regulation), mutagenesis of binding domains, ionic strength/heparin competition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — domain-level binding characterization with functional complement assays, multiple conditions tested\",\n      \"pmids\": [\"20855886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FHR-1 and FHR-5 bind to plasmid DNA and human genomic DNA, inhibiting FH binding to DNA and reducing FH cofactor activity. Both FHRs also bind to late apoptotic and necrotic cells, recruit monomeric CRP and pentraxin 3, and FHR-pentraxin interactions promote enhanced activation of both classical and alternative complement pathways on dead cells when exposed to human serum.\",\n      \"method\": \"Binding assays (ELISA, pulldown), complement activation assays on DNA and dead cells, cofactor activity assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple in vitro functional assays with defined mechanistic readouts\",\n      \"pmids\": [\"32765490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FHR1 binds extracellular matrix components laminin, fibromodulin, osteoadherin, and PRELP through its C-terminal CCP domains 4-5. FHR1 inhibits FH binding to these ECM ligands in a dose-dependent manner, reducing FH cofactor activity, and enhances alternative complement pathway activation on immobilized ECM proteins, resulting in increased C3-fragment, factor B, and C5b-9 deposition.\",\n      \"method\": \"Binding assays (ELISA/SPR), cofactor activity assay, complement activation assay on immobilized ECM proteins, domain mapping\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — domain-level binding mapped with functional complement consequence, multiple ECM ligands and orthogonal assays\",\n      \"pmids\": [\"35392081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A novel CFHR1/CFH hybrid fusion protein containing the first four SCRs of FHR1 and the terminal SCR20 of CFH acts as a competitive antagonist of FH. In an FH-dependent hemolysis assay, the hybrid protein caused sheep erythrocyte lysis, and sera from carriers induced more C5b-9 deposition on endothelial cells than control serum.\",\n      \"method\": \"FH-dependent hemolysis assay, C5b-9 deposition assay on endothelial cells, purification of hybrid protein from patient serum\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional assays with patient-derived and recombinant proteins, multiple readouts\",\n      \"pmids\": [\"24904082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The aHUS-associated FHR1*B isoform (CFHR1*B haplotype) exhibits higher C3b-binding capacity and stronger binding to necrotic cells than FHR1*A. FHR1*B shows stronger interference with FH-mediated cofactor function (less C3b cleavage) and stronger deregulation of FH inhibition of C3bBb assembly. FHR1*B also triggers higher IL-1β and IL-6 secretion from monocytes than FHR1*A.\",\n      \"method\": \"Homology modeling, recombinant protein expression, C3b binding assays, cofactor assay, C3 convertase assay, cytokine secretion assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays, single lab study\",\n      \"pmids\": [\"35126388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FHR-1 competes with FH for binding to Plasmodium falciparum surfaces (intraerythrocytic schizonts and merozoites). FHR-1 accumulates on parasite surfaces and impairs C3b inactivation and parasite viability; FHR-1-deficient serum showed increased FH binding to parasites, and adding recombinant FHR-1 decreased FH binding.\",\n      \"method\": \"Binding competition assays with FHR-1-deficient serum and recombinant FHR-1, C3b inactivation assay, parasite viability assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding competition confirmed with deficient serum and recombinant protein, functional consequence measured\",\n      \"pmids\": [\"30455399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Leptospiral immunoglobulin-like (Lig) proteins mediate acquisition of FHR-1 from human serum onto the Leptospira surface, contributing to bacterial complement evasion. Competition assays showed FH and C4BP have distinct binding sites on Lig proteins.\",\n      \"method\": \"Serum acquisition assays, pulldown, competition binding assays\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pulldown and competition assays demonstrating specific binding, single lab\",\n      \"pmids\": [\"22291192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Deletion of mouse Cfhr1 (FHR-E, the murine homolog of human FHR-1) enhanced LPS-induced alternative complement pathway activation both in vitro and in vivo, and Cfhr1 knockout mice exhibited more severe sepsis and acute kidney injury in response to LPS challenge, demonstrating that FHR-E/FHR-1 regulates the alternative pathway in vivo.\",\n      \"method\": \"Cfhr1 knockout mouse model, LPS-induced sepsis/AKI model, complement activation assays in vitro and in vivo\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO mouse with defined phenotypic readout in vivo and in vitro\",\n      \"pmids\": [\"32636836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FHR1 accumulates below the retinal pigment epithelium (RPE) in AMD. FHR1 signals through the receptor EMR2 (EGF-like module-containing mucin-like hormone receptor 1) on RPE and mononuclear phagocytes (MPs) to induce Ca2+ signaling and gene expression changes. muFHR1 deletion in mice significantly reduced mononuclear phagocyte invasion and neoangiogenesis in laser-induced choroidal neovascularization (CNV) model, establishing an EMR2-dependent FHR1 signaling pathway promoting para-inflammation.\",\n      \"method\": \"AMD donor tissue immunostaining, murine AMD models (RNAseq), EMR2 receptor identification, Ca2+ signaling assay in RPE cells, muFHR1 KO mouse in laser-induced CNV model\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor identification with Ca2+ signaling assay and KO mouse model with defined phenotype, single study\",\n      \"pmids\": [\"40611130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CFHR1-modified neural stem cells (NSCs) blocked complement activation cascade and inhibited membrane attack complex formation in a neuromyelitis optica spectrum disorder model, protecting endogenous and transplanted NSC-differentiated astrocytes from immune-mediated damage.\",\n      \"method\": \"Engineered NSC transplantation in NMOSD model, complement activation assay, MAC formation assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — functional in vivo model with complement-specific readouts, single lab\",\n      \"pmids\": [\"27671112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Deletion of muFHR1 (mouse homolog of FHR-1) in ApoE-/- mice normalized cholesterol levels, reduced inflammation and plaque formation. muFHR1 deletion enhanced lipid conversion in the liver (RNAseq), and muFHR1 was found to direct oxLDL uptake by macrophages, supporting foam cell formation and plaque development.\",\n      \"method\": \"muFHR1-/- ApoE-/- double knockout mouse model, RNAseq, cholesterol measurements, plaque quantification\",\n      \"journal\": \"International journal of medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO mouse with defined atherosclerosis phenotype, RNAseq mechanistic support\",\n      \"pmids\": [\"41583528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FHR-1 circulates on extracellular vesicles and is deposited in atherosclerotic plaques. Surface-bound FHR-1 induces expression of pro-inflammatory cytokines and tissue factor in monocytes and neutrophils.\",\n      \"method\": \"Isolation of FHR-1 from plasma/extracellular vesicles, immunostaining of plaques, cytokine/tissue factor induction assays in monocytes and neutrophils\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple cell-based functional assays with protein isolated from human plasma, single lab\",\n      \"pmids\": [\"34795372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Patients lacking CFHR1 (but not those lacking CFHR3 alone) present with anti-FH autoantibodies, suggesting that CFHR1 deficiency specifically promotes generation of anti-CFH autoantibodies, possibly due to lack of CFHR1 as an immune tolerance antigen sharing epitopes with CFH.\",\n      \"method\": \"Proteomics strategy to analyze CFHR proteins in plasma, genotype-phenotype correlation in aHUS cohorts\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genotype-phenotype correlation with proteomics validation, replicated across patient cohorts\",\n      \"pmids\": [\"19745068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cfhr1 gene knockout in mice led to excessive alternative complement pathway activation and enhanced C3a formation in lung tissues following S. aureus infection, resulting in higher bacterial loads in lungs and exacerbated sepsis-induced acute lung injury.\",\n      \"method\": \"Cfhr1-knockout mouse model, S. aureus i.v. infection model, C3a measurement, bacterial CFU counts, cytokine/complement factor measurements, RNA-seq\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO mouse with defined infectious phenotype and complement readout, single lab\",\n      \"pmids\": [\"39128222\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CFHR1 (FHR-1) is a circulating plasma complement protein that forms homo- and heterodimers/oligomers via conserved N-terminal domains, and acts primarily as a context-dependent modulator of complement activation: on cell surfaces and extracellular matrices it competes with CFH for C3b/C3dg binding (via its C-terminal SCR3-5 domains) to derepress complement, inhibits C5 convertase and MAC formation, binds necrotic cells via its N-terminus to trigger NLRP3 inflammasome activation through the EMR2 G-protein coupled receptor (independent of complement), and can bind ECM components, DNA, pentraxins (CRP, PTX3), and microbial surfaces—collectively indicating that FHR-1 fine-tunes the balance between complement activation and suppression while also driving sterile inflammation at sites of necrosis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CFHR1 (FHR-1) is a secreted complement regulatory protein that fine-tunes the balance between complement activation and suppression on cell surfaces, extracellular matrices, and microbial surfaces, while also driving complement-independent sterile inflammation. FHR-1 circulates as homo- and heterodimers (with FHR-2) whose N-terminal dimerization domains are required for effective C3b/C3d binding; its C-terminal SCR3–5 domains share the same C3b-binding interface as CFH SCR19-20, enabling dose-dependent competition with CFH that displaces CFH cofactor activity and promotes alternative pathway amplification on surfaces including ECM components (laminin, fibromodulin), DNA, necrotic cells, pentraxins (monomeric CRP, PTX3), and microbial targets [PMID:27814381, PMID:23728178, PMID:35392081, PMID:32765490, PMID:28533443]. While FHR-1 can inhibit C5 convertase and terminal complement complex formation under certain conditions [PMID:19528535], murine knockout studies demonstrate that loss of FHR-1 leads to excessive alternative pathway activation and worsened sepsis-associated organ injury, confirming a net regulatory role in vivo [PMID:32636836, PMID:39128222]. Independently of complement, FHR-1 binds necrotic cells via its N-terminus and signals through the GPCR EMR2 to activate the NLRP3 inflammasome via the phospholipase C pathway, driving IL-1β, TNFα, and IL-6 secretion from monocytes, and promoting mononuclear phagocyte invasion and neoangiogenesis in retinal disease models [PMID:31273197, PMID:40611130].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Establishing that FHR-1 acts at the terminal complement pathway: FHR-1 was shown to inhibit C5 convertase and MAC formation independently of CFH's C3 convertase regulation, revealing a distinct level of complement control and raising the question of how FHR-1 and CFH partition regulatory functions on surfaces.\",\n      \"evidence\": \"In vitro C5 convertase inhibition, C5b deposition, and MAC formation assays with binding competition on cell surfaces\",\n      \"pmids\": [\"19528535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether FHR-1 C5 convertase inhibition operates in vivo\",\n        \"Whether terminal pathway regulation is the dominant activity or context-dependent\",\n        \"The structural basis for C5 convertase recognition by FHR-1\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linking CFHR1 deficiency to autoimmune pathology: CFHR1-deficient aHUS patients specifically generated anti-FH autoantibodies, suggesting FHR-1 may serve as an immune tolerance antigen for CFH due to shared epitopes.\",\n      \"evidence\": \"Proteomics of CFHR proteins in plasma combined with genotype-phenotype correlation in aHUS cohorts\",\n      \"pmids\": [\"19745068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism of tolerance breakdown in CFHR1 deficiency not demonstrated experimentally\",\n        \"Correlation does not establish causality — could reflect linked deletions\",\n        \"No B-cell or T-cell epitope mapping performed\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating microbial surface exploitation: FHR-1 was recruited to group A streptococcal surfaces via Scl1 proteins through its C-terminal SCR3–5, displacing CFH and thereby shifting complement regulation from C3 convertase to terminal pathway level.\",\n      \"evidence\": \"Pulldown and competition binding assays with domain mutagenesis and complement functional assays on streptococcal surfaces\",\n      \"pmids\": [\"20855886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo relevance of FHR-1 recruitment in streptococcal infection not established\",\n        \"Whether this mechanism extends to other Gram-positive pathogens\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealing that dimerization/oligomerization is functionally critical: native FHR-1 circulates as dimers that enhance avidity for C3b/iC3b/C3dg; a C3G-associated CFHR1 N-terminal duplication created abnormally large multimers with pathologically enhanced CFH competition, establishing that oligomeric state directly controls complement deregulatory potency.\",\n      \"evidence\": \"SPR, hemolytic assays, and biochemical analysis of patient-derived mutant FHR1 oligomers\",\n      \"pmids\": [\"23728178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"High-resolution structure of the dimerization interface not determined\",\n        \"How oligomeric state is regulated in vivo\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Establishing fusion proteins as competitive antagonists of CFH: a naturally occurring CFHR1/CFH hybrid protein containing FHR-1 N-terminal dimerization domains fused to CFH SCR20 competed with FH and caused complement-mediated hemolysis and C5b-9 deposition on endothelial cells.\",\n      \"evidence\": \"FH-dependent hemolysis assay and C5b-9 deposition on endothelial cells with patient-derived hybrid protein\",\n      \"pmids\": [\"24904082\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Prevalence and penetrance of hybrid gene in broader populations\",\n        \"Whether hybrid formation requires specific genomic rearrangement hotspots\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining the structural basis for CFH competition: mutagenesis showed that FHR-1 dimerization is necessary for C3b/C3d binding, that the binding interface is identical to CFH SCR19-20, and that FHR-1 sterically blocks both C-terminal and N-terminal CFH interactions with C3b, unifying the competitive deregulation model.\",\n      \"evidence\": \"Site-directed mutagenesis, ELISA binding assays, and hemolytic functional assays\",\n      \"pmids\": [\"27814381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Crystal or cryo-EM structure of FHR-1 dimer bound to C3b not available\",\n        \"Relative affinities under physiological conditions on cell surfaces\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolving how FHR-1 promotes complement activation on damaged tissues: FHR-1 binds monomeric CRP and permits C3 convertase formation on ECM and necrotic cells, enhancing both classical and alternative pathway activation — contradicting the earlier view that FHR-1 primarily inhibits terminal complement.\",\n      \"evidence\": \"ELISA binding assays, complement activation assays on ECM and necrotic cell surfaces, C3 convertase formation assay\",\n      \"pmids\": [\"28533443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which activity predominates in vivo — complement inhibition or activation — remains context-dependent\",\n        \"Whether CRP conformational state is controlled at injury sites\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Characterizing the dynamics of FHR dimeric pools: FRET demonstrated rapid monomer exchange between FHR-1 homodimers and FHR-1/FHR-2 heterodimers in plasma, and CFHR1-deletion individuals confirmed loss of all FHR-1-containing dimers.\",\n      \"evidence\": \"FRET, ELISA, and ex vivo serum analysis from CFHR1-deletion individuals\",\n      \"pmids\": [\"29093712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional differences between FHR-1/1 homodimers and FHR-1/2 heterodimers not defined\",\n        \"Whether monomer exchange is regulated or stochastic\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovering a complement-independent inflammatory function: FHR-1 binds necrotic cells via its N-terminus and signals through the GPCR EMR2 to activate the NLRP3 inflammasome via the PLC pathway, inducing IL-1β, TNFα, IL-18, and IL-6 secretion from monocytes — a function unique to FHR-1 among FHR family members.\",\n      \"evidence\": \"In vitro binding, inflammasome activation, cytokine ELISA, EMR2 receptor identification, PLC pathway pharmacological inhibition, patient tissue staining\",\n      \"pmids\": [\"31273197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The FHR-1/EMR2 binding interface not structurally defined\",\n        \"Whether other cell types respond to FHR-1 via EMR2\",\n        \"In vivo contribution of FHR-1–EMR2 axis to sterile inflammation not demonstrated at that time\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extending FHR-1 to atherosclerosis: FHR-1 was found on circulating extracellular vesicles and deposited in atherosclerotic plaques, where surface-bound FHR-1 induced proinflammatory cytokine and tissue factor expression in monocytes and neutrophils.\",\n      \"evidence\": \"Isolation from plasma EVs, immunostaining of human plaques, cytokine/tissue factor induction assays\",\n      \"pmids\": [\"34795372\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal role of FHR-1 in plaque formation not established by this study alone\",\n        \"Whether EV-associated FHR-1 has different activity than soluble FHR-1\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating in vivo complement regulatory role: Cfhr1 knockout mice showed enhanced alternative pathway activation and more severe sepsis/acute kidney injury upon LPS challenge, establishing that FHR-1 has a net protective, complement-dampening function in vivo during endotoxemia.\",\n      \"evidence\": \"Cfhr1 knockout mouse model with LPS-induced sepsis/AKI, complement activation assays in vitro and in vivo\",\n      \"pmids\": [\"32636836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mouse FHR-E is not identical to human FHR-1 — species-specific differences in complement regulation\",\n        \"Whether the in vivo effect is direct C5 convertase inhibition or indirect via CFH modulation\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Broadening ligand repertoire to DNA and pentraxins: FHR-1 binds DNA, recruits monomeric CRP and PTX3 to dead cells, and inhibits FH binding to DNA, collectively enhancing complement activation via both classical and alternative pathways on apoptotic/necrotic surfaces.\",\n      \"evidence\": \"ELISA/pulldown binding assays, complement activation assays on DNA and dead cells, cofactor activity assays\",\n      \"pmids\": [\"32765490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether DNA-bound FHR-1 contributes to lupus-like autoimmunity\",\n        \"Relative contributions of CRP vs PTX3 recruitment in vivo\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolving why FHR-1 does not normally compete with CFH on host cells: wild-type FHR-1 lacks sialic acid binding capacity, preventing effective competition on sialylated host surfaces; aHUS-associated mutations confer sialic acid binding, enabling pathological CFH displacement and surface complement activation.\",\n      \"evidence\": \"NMR spectroscopy, biochemical binding assays, computational modeling of FHR-1 mutants, functional complement activation assays\",\n      \"pmids\": [\"33651882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether sialic acid binding distinguishes pathogenic from benign FHR-1 variants genome-wide\",\n        \"Structural mechanism of sialic acid recognition by mutant FHR-1\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining ECM as a major surface for FHR-1 activity: FHR-1 binds laminin, fibromodulin, osteoadherin, and PRELP via CCP4-5, displaces FH, and enhances alternative pathway activation with increased C3-fragment, factor B, and C5b-9 deposition on ECM surfaces.\",\n      \"evidence\": \"ELISA/SPR binding, domain mapping, cofactor activity, and complement activation on immobilized ECM proteins\",\n      \"pmids\": [\"35392081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether ECM-bound FHR-1 contributes to fibrosis or tissue remodeling\",\n        \"In vivo validation of FHR-1 ECM interactions\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing that natural FHR-1 isoform variation modulates disease risk: the aHUS-associated FHR1*B isoform shows higher C3b binding, stronger CFH displacement, and greater inflammasome-activating capacity compared to FHR1*A, connecting common polymorphism to quantitative differences in both complement and inflammatory outputs.\",\n      \"evidence\": \"Recombinant FHR1*A vs *B proteins tested in C3b binding, cofactor, C3 convertase, and cytokine secretion assays\",\n      \"pmids\": [\"35126388\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab study — independent replication needed\",\n        \"Population-level contribution of FHR1*B to aHUS risk not quantified\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connecting FHR-1 to metabolic inflammation: muFHR1 knockout in ApoE-/- mice normalized cholesterol, reduced plaque formation, and decreased foam cell development, with muFHR1 shown to direct oxLDL uptake by macrophages.\",\n      \"evidence\": \"muFHR1-/- ApoE-/- double knockout mouse model with RNAseq, cholesterol measurements, and plaque quantification\",\n      \"pmids\": [\"41583528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism of FHR-1-mediated oxLDL uptake not defined at receptor level\",\n        \"Mouse-to-human translatability of metabolic phenotype uncertain\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Validating the FHR-1/EMR2 axis in vivo in retinal disease: FHR-1 accumulates sub-RPE in AMD, signals through EMR2 on RPE and phagocytes to induce Ca2+ flux and transcriptional changes, and muFHR1 deletion significantly reduced phagocyte invasion and neoangiogenesis in laser-induced CNV, establishing a para-inflammatory signaling role in AMD.\",\n      \"evidence\": \"AMD donor tissue immunostaining, EMR2 receptor identification, Ca2+ signaling in RPE cells, muFHR1 KO mouse in laser-induced CNV model\",\n      \"pmids\": [\"40611130\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether therapeutic FHR-1 blockade or EMR2 antagonism protects against AMD progression\",\n        \"Contribution of complement-dependent vs complement-independent FHR-1 effects in the retina\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Open question: the context-dependent switch between FHR-1's complement-activating and complement-inhibiting functions, the structural basis of FHR-1/EMR2 signaling, and whether FHR-1 can be therapeutically targeted in complement-mediated and inflammatory diseases remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No high-resolution structure of FHR-1 dimer or FHR-1/EMR2 complex available\",\n        \"Quantitative partitioning of complement-inhibitory vs complement-activating functions across tissues and disease states not defined\",\n        \"No clinical trials targeting FHR-1 or the FHR-1/EMR2 axis reported\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6, 9]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [5, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 4, 8, 18]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6, 7, 8, 9, 14, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 15]}\n    ],\n    \"complexes\": [\n      \"FHR-1 homodimer\",\n      \"FHR-1/FHR-2 heterodimer\"\n    ],\n    \"partners\": [\n      \"CFH\",\n      \"FHR2\",\n      \"C3b\",\n      \"EMR2\",\n      \"CRP\",\n      \"PTX3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}